Patent SG-11201808979U-A (SG)
Title: Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
Inventor: LOO DERYK
IPC: C07K16/28
Filed: 2017-04-13
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110111111011111111110111001111101111011111 International Bureau 0.. .... .. ..... ..or::,„,' (10) International Publication Number (43) International Publication Date WO 2017/180813 Al 19 October 2017(19.10.2017) WIPO I PCT (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/28 A61K 47/68 (2017.01) (21) International Application Number: (22) International Filing Date: 13 (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/323,228 15 April 2016 62/323,249 15 April 2016 62/432,314 9 December 2016 (71) Applicant: MACROGENICS, INC. ical Center Drive, Rockville, MD (72) Inventors: LOO, Deryk, T.; 1509 mont, CA 94402 (US). HUANG, Lane, Bethesda, MS 20817 (US). (74) Agents: AUERBACH, Jeffrey, I. et al.; AuerbachSchrot (2006.01) LLC, 2200 Research Blvd., Suite 560, Rockville, MD 20850 (US). (81) Designated States (unless otherwise indicated, for every PCT/US2017/027317 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, April 2017 (13.04.2017) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, English MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (15.04.2016) US RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (15.04.2016) US TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (09.12.2016) US ZA, ZM, ZW. [US/US]; 9704 Med- (84) Designated States (unless otherwise indicated, for every 20850 (US). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Pine Knoll Drive, Bel- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Ling; 8210 Moorland TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, JOHNSON, Leslie, S.; DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MD 20874 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, San Francisco, CA SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 1217 Oak Grove Av- GW, KM, ML, MR, NE, SN, TD, TG). 94010 (US). BONVINI, Potomac, MD 20854 Published: — with international search report (Art. 21(3)) [Continued on next page] — 14411 Poplar Hill Road, Darnestown, _ SON, Thomas; 1390 39th Avenue, 94122 (US). SCRIBNER, Juniper; = Apt Burlingame, enue, #4, CA Ezio; 11136 Powder Horn Drive, (US). = MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE - Calu-6 Cells Multiple Dose in vivo Efficacy Study -0- Vehicle (PBS) -El- hmAb-C-DUBA [6mg/kg x 3] iv -is- hmAb-C-DUBA [3mg/kg x 3] -v- hmAb-C-DUBA [1mg/kg x 3] , -. V \"' '' . -- - • ''\"=\" 111 • 1611611 \"-••••• (54) Title: NOVEL B7-H3 BINDING THEREOF = = _ — hmAb-C-DUBA = 2600 = — ... 2400 ''' E 2200 E 2000 1800 = c o 1600 1400 — 1200 z > 1000 = — 8 800 E 600 z 400 I - 200 _ 0 20 40 60 Study Day Figure 16 directed to novel B7-H3-binding molecules capable of binding to human and non-human that are cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey). B7-H3-binding molecules that comprise Variable Light Chain and/or Variable Heavy Chain and/or deimmunized so as to exhibit a reduced immunogenicity upon administration to re- pertains to bispecific, trispecific or multispecific B7-H3-binding molecules, including antibodies, trivalent binding molecules, etc. that comprise: (i) such B7-H3-binding Variable binding to an epitope of a molecule present on the surface of an effector cell. The invention that comprises the human B7-H3 binding domain of a humanized anti-human B7-H3 anti - (a \"B7-H3-ADC\"). 11 M ,-1 cc 51 (57) : The present invention is w w B7-H3, and in particular to such molecules 1-1 ---- The invention additionally pertains to L . ' (VH) Domains that have been humanized cipient subjects. The invention particularly ei bispecific diabodies, BiTEs, bispecific O Domains and (ii) a domain capable of also particularly pertains to a molecule P.- body conjugated to at least one drug moiety WO 2017/180813 Al MIDEDIMOM010101111101010MOUMOIRMEDIONEVOIMIE — before the expiration of the time limit for amending the — with sequence listing part of description (Rule 5.2(a)) claims and amendments (Rule to be republished 48.2(h)) in the event of receipt of